5 results
The current study is set up to validate the working mechanism of the current design of the FemFlow.
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…
The primary objective of the study is to demonstrate the safety of the investigational device (GRADION* Hip Total Cartilage Replacement (TCR)* ).
Primary Objective: This study is set up to validate the patient comfort of the current design of the FemFlow. For the validation of the patient comfort, the FemFlow will be rated on:Comfort during insertion Comfort of an alien object in the bladder…
Primary objective* To study the antitumor activity and safety of crizotinib across predefined tumor types in patients whose tumors are harboring specific alterations in ALK and/or METSecondary objectives* To study the specificity of the kinase…